Summit Therapeutics Inc. develops oncology medicines led by ivonescimab, an investigational PD-1 / VEGF bispecific antibody in-licensed from Akeso. The company reports clinical and operational updates for ivonescimab programs in non-small cell lung cancer and colorectal cancer, including multiregional Phase III studies and data presentations from HARMONi trials.
Recurring Summit Therapeutics news also covers financial results, regulatory updates tied to the accepted Biologics License Application for ivonescimab in EGFR-mutated non-squamous NSCLC after tyrosine kinase inhibitor therapy, clinical trial collaborations, and equity-compensation actions under Nasdaq rules. Summit holds development and commercialization rights for ivonescimab across North America, South America, Europe, the Middle East, Africa, and Japan.
Summit Therapeutics has appointed Michael Donaldson as its new Chief Financial Officer, effective immediately. Donaldson brings over 20 years of finance experience, especially in corporate finance. He previously held leadership positions at Goldfinch Bio and ARIAD Pharmaceuticals, contributing to significant acquisitions. The company's ongoing Phase 3 clinical trials for its antibiotic candidate, ridinilazole, hold promise for treating C. difficile infections. Summit aims to innovate in antibiotic development to improve patient outcomes while maintaining a focus on financial solutions.
Summit Therapeutics plc (NASDAQ: SMMT) reported its financial results for Q1 2020, highlighting a cash balance of $55.3 million as of March 31, down from $60.3 million at the end of 2019. The company posted a loss of $6.1 million, an improvement over the $6.9 million loss in Q1 2019. The Phase 3 Ri-CoDIFy clinical trials for ridinilazole have enrolled 291 patients as of May 31, 2020, though patient enrollment has been negatively affected by COVID-19 uncertainties, leading to the withdrawal of public commentary on trial completion timelines.
Summary not available.